03:00 Thu 25 Jun 2020
Directa Plus PLC - Gipave graphene asphalt trial in Kent
("Directa Plus" or the "Company")
Gipave graphene asphalt trial in
Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, announces that the Company supplied Gipave, the Company's proprietary asphalt supermodifier, for use in a road trial in
Directa is working in collaboration with its industrial partner
This follows previously announced trials in
Commenting,
-ends-
For further information please visit http://www.directa-plus.com/ or contact:
| +39 02 36714458 |
|
|
|
|
| +44 20 7894 7000 |
|
|
N+1 Singer (Joint Broker) | +44 20 7496 3069 |
|
|
Tavistock (Financial PR and IR) | +44 20 7920 3150 |
|
|
About Directa Plus
Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product) and textiles (based on our G+ products). In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products. All our products are hypoallergenic, non-toxic and sustainably produced.
This information is provided by RNS, the news service of the
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE